AnaptysBio: Trial of Jemperli Drug Meets Primary Endpoint
03 December 2022 - 02:11AM
Dow Jones News
By Dean Seal
AnaptysBio Inc. said Friday that a recent trial studying
endometrial cancer treatment dostarlimab, known by the brand name
Jemperli, met its primary endpoint of investigator-assessed
progression-free survival.
The San Diego, Calif., clinical-stage biotechnology company
reported that GSK PLC's Phase 3 trial, which treated chemotherapy
patients with advanced or recurrent endometrial cancer, showed that
Jemperli provided a statistically significant and clinically
meaningful progression-free survival benefit in a prespecified
subgroup of patients who were mismatch-repair deficient and
microsatellite instability-high.
Jemperli also provided a benefit in progression-free survival
for a subgroup of patients who were mismatch-repair proficient and
microsatellite stable, AnaptysBio said.
Although overall survival data is still premature at this time,
the company said a favorable trend was observed in the overall
population.
Regulatory submissions based on the trials are expected in the
first half of 2023, the company said.
Jemperli was discovered by AnaptysBio and licensed to Tesaro
Inc., now a part of GSK, under a collaboration and exclusive
license agreement signed in March 2014.
AnaptysBio's shares were up 2.9% to $28.07 in premarket trading
Friday.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 02, 2022 09:56 ET (14:56 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Feb 2024 to Mar 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Mar 2023 to Mar 2024